NYSE:ABT

ABBOTT LABORATORIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Abbott Laboratories - ABT

Retrieved on: 
Saturday, March 4, 2023
Class Action Lawsuit, Professional Services, Legal, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cronobacter, Food, Abbott Laboratories, Infant, FDA, Death, NYSE, OSHA, Laboratory, KSF

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Abbott Laboratories (NYSE: ABT).

Key Points: 
  • Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Abbott Laboratories (NYSE: ABT).
  • KSF’s investigation is focusing on whether Abbott’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms.
  • KSF has offices in New York, California, Louisiana and New Jersey.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO), Cardiovascular Systems, Inc. (Nasdaq – CSII)

Retrieved on: 
Wednesday, February 22, 2023
Cardiovascular System Dynamics Society, Brodsky, Globus Medical, Tripura Merger Agreement, NYSE, CVS, Argo, ABT, Oak Street Health, Security (finance)

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • NUVASIVE shareholders will receive 0.75 of a share of Globus Medical Class A common stock for each share of NUVASIVE common stock owned at the closing of the transaction.
  • Under the terms of the Merger Agreement, Oak Street Health be acquired by CVS Health® (“CVS”) (NYSE - CVS).
  • Oak Street Health stockholders will receive $39.00 per share in an all-cash transaction, representing an enterprise value of approximately $10.6 billion.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO), Cardiovascular Systems, Inc. (Nasdaq – CSII)

Retrieved on: 
Tuesday, February 14, 2023
Tripura Merger Agreement, ABT, Globus Medical, Brodsky, NYSE, CVS, Argo, Cardiovascular System Dynamics Society, Oak Street Health, Security (finance)

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • NUVASIVE shareholders will receive 0.75 of a share of Globus Medical Class A common stock for each share of NUVASIVE common stock owned at the closing of the transaction.
  • Under the terms of the Merger Agreement, Oak Street Health be acquired by CVS Health® (“CVS”) (NYSE - CVS).
  • Oak Street Health stockholders will receive $39.00 per share in an all-cash transaction, representing an enterprise value of approximately $10.6 billion.

FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy

Retrieved on: 
Thursday, January 26, 2023
Diabetic neuropathy, Pain, Spinal cord stimulator, Spine, Nerve, XR, Peripheral neuropathy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Wi-Fi, The Proclaimers, NYSE, Glucose, Pain management, FDA, Physician, Diabetes, Hypoesthesia, FIPP, SCS, DPN, Patient, Quality of life, Longevity, Food, Disease, Chronic pain, Pharmaceutical industry, Medical device, Dentistry, MD

ABBOTT PARK, Ill., Jan. 26, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved its Proclaim™ XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes.

Key Points: 
  • ABBOTT PARK, Ill., Jan. 26, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved its Proclaim™ XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes.
  • The Proclaim XR SCS system can provide relief to DPN patients in need of alternatives to traditional treatment approaches, such as oral medication.
  • Approved for the treatment of chronic pain in 2019, the Proclaim XR SCS system now offers DPN patients relief from chronic pain by delivering low amounts, or doses, of stimulation.
  • For U.S. important safety information on the Abbott Proclaim™ XR SCS system, visit: https://www.neuromodulation.abbott/us/en/important-safety-info/ht-tab/pr...™-xr-and-prodigy™-scs-systems.html .

Abbott Receives FDA Approval for Navitor™, a Next-Generation TAVI System Designed to Treat Aortic Stenosis

Retrieved on: 
Tuesday, January 17, 2023
Blood, Frailty, PVL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Aortic stenosis, Death, FDA, Risk, Hemodynamics, NYSE, Coronary artery disease, Health, Family, Houston Methodist Hospital, Food, Patient, Heart failure, TAVI, Degenerative disease, Physician, Medical device, Medical imaging

Aortic stenosis occurs when the aortic valve's opening narrows, restricting blood flow to the body.

Key Points: 
  • Aortic stenosis occurs when the aortic valve's opening narrows, restricting blood flow to the body.
  • "The innovative Navitor system also offers physicians stable and accurate device placement, even in challenging patient anatomies."
  • "Navitor is the first TAVI system to offer optimal hemodynamics in all valve sizes while also preserving options for lifetime disease management, an important consideration for physicians and patients when selecting a TAVI solution.
  • Receiving this approval is a major next step in our mission to help people live better lives through better health."

ABBOTT ALERT: Bragar Eagel & Squire, P.C. is Investigating Abbott Laboratories on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, January 20, 2023
Class Action Lawsuit, Professional Services, Legal, Similac, News, Laboratory, Death, Safety, FDA, NYSE, Bacteria, United, Jeanne Eagels, Telephone, Abbott Laboratories, Complaint, US Foods, Labor Day, Infant, P.C, OSHA, Medical device

Our investigation concerns whether the board of directors of Abbott have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Abbott have breached their fiduciary duties to the company.
  • Abbott manufactures various forms of infant formula including formula sold under the brand names Similac, Alimentum, and EleCare.
  • Prior to February 2022, Abbott had produced 40% of the United States’ infant formula.
  • On February 17, 2022, the US Food and Drug Administration (“FDA”) announced it was investigating four consumer complaints of infant illness related to powdered infant formula produced by Abbott Laboratories in Sturgis.

Abbott, Blood Centers of America Launch First-of-its-Kind Mixed Reality Experience for Use During Blood Donation

Retrieved on: 
Saturday, January 7, 2023
Innovation, Blood, Microsoft, Health, Virtual reality, BCA, Research, World Blood Donor Day, CES, LAS, Consumer Electronics Show, Flower, Plasma, NYSE, Music, HoloLens 2, Seed, Environment, Video game console, Medical device, Pharmaceutical industry

Mixed reality offers donors an innovative, immersive digital experience while giving blood

Key Points: 
  • Mixed reality offers donors an innovative, immersive digital experience while giving blood
    The Abbott technology is one of the first-ever, consumer-focused mixed reality applications completely controlled through eye tracking
    Innovation aims to improve the experience and attract new, younger blood donors by adding an element of high-tech mixed reality
    LAS VEGAS, Jan. 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) and Blood Centers of America are unveiling an innovative new mixed reality experience for use during blood donation.
  • The mixed reality technology is an immersive digital experience designed to improve the blood donation process, attract new donors and motivate a younger generation to give blood.
  • The mixed reality experience allows blood donation professionals to safely conduct the donation and interact with donors at every step of the process.
  • The mixed reality experience was designed based on research that natural settings are the most preferred environment as donors give blood.

Abbott Hosts Conference Call for Fourth-Quarter Earnings

Retrieved on: 
Wednesday, January 4, 2023
NYSE, EAS (nutrition brand), Life

ABBOTT PARK, Ill., Jan. 4, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2022 financial results on Wednesday, Jan. 25, 2023, before the market opens.

Key Points: 
  • ABBOTT PARK, Ill., Jan. 4, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2022 financial results on Wednesday, Jan. 25, 2023, before the market opens.
  • The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com .
  • Abbott is a global healthcare leader that helps people live more fully at all stages of life.
  • Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines.

Abbott's FreeStyle Libre® 3 Integrated with Automated Insulin Delivery System mylife™ Loop in Germany

Retrieved on: 
Wednesday, December 21, 2022
Consensus, FreeStyle, NYSE, AID, International Diabetes Center at Park Nicollet, Loop, Continuous glucose monitor, FX, JDRF, American Diabetes Association, Life, T1D, European Association for the Study of Diabetes, Disability, Multimedia, Nutritional immunology, Insulin, Medical device, Pharmaceutical industry, Diabetes

This automated insulin delivery system (AID) solution is now available in Germany and will be available in additional European countries beginning in 2023.

Key Points: 
  • This automated insulin delivery system (AID) solution is now available in Germany and will be available in additional European countries beginning in 2023.
  • Nearly five healthy years could be restored if they had access to devices that monitor glucose and automate insulin delivery.
  • "Technological innovations, like automated insulin delivery systems, can ease some of that uncertainty by continuously monitoring a person's glucose levels and delivering the right insulin dosage, which can ultimately improve time in range.
  • In addition to partnering with Ypsomed and CamDiab, Abbott is working to make the FreeStyle Libre platform interoperable with other leading insulin delivery systems.

Abbott to Present at J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, December 20, 2022
NYSE, EAS (nutrition brand), Life, Conference

ABBOTT PARK, Ill., Dec. 20, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023.

Key Points: 
  • ABBOTT PARK, Ill., Dec. 20, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023.
  • Robert B. Ford, chairman and chief executive officer, will present at 11 a.m. Central time.
  • Abbott is a global healthcare leader that helps people live more fully at all stages of life.
  • Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines.